- •Patients’ preferences should be considered in RRMS treatment decisions.
- •We aimed to understand factors driving status quo bias in early-stage RRMS patients.
- •Over forty percent of patients suffer cognitive delays in the early stages of RRMS.
- •Despite evidence of disease progression, patients tend to maintain their treatment.
- •Disease severity perception and cognitive delays affect patients’ treatment choices.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves.J. Neurol. Neurosurg. Psychiatry. 2005; 76: 744-749https://doi.org/10.1136/jnnp.2004.045518
- People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures.Disabil. Health J. 2018; 11: 99-107https://doi.org/10.1016/j.dhjo.2017.04.008
- Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.Mult. Scler. 2017; 23: 721-733https://doi.org/10.1177/1352458517690821
- I'm walking into the unknown": qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment.Mult. Scler. Relat. Disord. 2022; 58103464https://doi.org/10.1016/j.msard.2021.103464
- Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis.Sci. Rep. 2019; 2 (9): 18074https://doi.org/10.1038/s41598-019-54153-7
- Escalation vs. early intense therapy in multiple sclerosis.J. Pers. Med. 2022; 12https://doi.org/10.3390/jpm12010119
- Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?.J. Neurol. Neurosurg. Psychiatry. 2018; 89: 844-850https://doi.org/10.1136/jnnp-2017-317509
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.J. Neurol. Neurosurg. Psychiatry. 2018; 89: 1200-1207https://doi.org/10.1136/jnnp-2018-318228
- Cognitive impairment in multiple sclerosis.Lancet Neurol. 2008; 7: 1139-1151https://doi.org/10.1016/S1474-4422(08)70259-X
- Shared decision making and autonomy among US participants with multiple sclerosis in the NARCOMS registry.Int. J. MS Care. 2017; 19: 303-312https://doi.org/10.7224/1537-2073.2016-091
- Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.J. Neurol. 2018; 265: 1328-1333https://doi.org/10.1007/s00415-018-8836-5
- Do people with multiple sclerosis want to know their prognosis? A UK nationwide study.PLoS ONE. 2018; 13e0193407https://doi.org/10.1371/journal.pone.0193407
- Individual risk attitudes: measurement, determinants, and behavioral consequences.J. Eur. Econ. Assoc. 2011; 9: 522-550https://doi.org/10.1111/j.1542-4774.2011.01015.x
- The state-trait hopelessness scale: development and testing.West. J. Nurs. Res. 2014; 36: 552-570https://doi.org/10.1177/0193945913507634
- Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.Mult. Scler. Relat. Disord. 2019; 29: 86-93https://doi.org/10.1016/j.msard.2019.01.031
- Multilevel (hierarchical) modeling: what it can and cannot do.Technometrics. 2006; 48: 432-435https://doi.org/10.1198/004017005000000661
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M.P., Thalheim, C., Traboulsee, A., Vollmer, T., 2015. Brain health: time matters in multiple sclerosis.
- SymptoMScreen: a tool for rapid assessment of symptom severity in MS across multiple domains.Appl. Neuropsychol. Adult. 2017; 24: 183-189https://doi.org/10.1080/23279095.2015.1125905
- Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis.Brain. 2021; 144: 162-185https://doi.org/10.1093/brain/awaa385
- The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite.Mult. Scler. 2000; 6: 286-290https://doi.org/10.1177/135245850000600411
- Estimating the prevalence of cognition and mental health among multiple sclerosis patients: a population-based cross-sectional study.Mult. Scler. Relat. Disord. 2019; 36101391https://doi.org/10.1016/j.msard.2019.101391
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452https://doi.org/10.1212/wnl.33.11.1444
- Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.J. Neurol. 2020; 267: 3489-3498https://doi.org/10.1007/s00415-019-09395-w
- A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.BMC Neurol. 2015; 15: 40https://doi.org/10.1186/s12883-015-0296-2
- Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis.Mult. Scler. Relat. Disord. 2019; 35: 7-15https://doi.org/10.1016/j.msard.2019.06.036
- Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study.Ther. Adv. Neurol. Disord. 2016; 9: 287-296https://doi.org/10.1177/1756285616648060
- Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis.Mult. Scler. 2005; 11: 69-75https://doi.org/10.1191/1352458505ms1110oa
- High-efficacy disease-modifying therapies in people with relapsing-remitting multiple sclerosis: the role of risk attitude in treatment decisions.Patient. 2021; 14: 241-248https://doi.org/10.1007/s40271-020-00454-3
- Diagnosis and treatment of multiple sclerosis: a review.JAMA. 2021; 325: 765-779https://doi.org/10.1001/jama.2020.26858
- Cognitive dysfunction in early multiple sclerosis: a review.QJM. 2018; 111: 359-364https://doi.org/10.1093/qjmed/hcx070
- Psychometric properties of the SymptoMScreen questionnaire in a mild disability population of patients with relapsing-remitting multiple sclerosis: quantifying the patient's perspective.Neurol. Ther. 2020; 9: 173-179https://doi.org/10.1007/s40120-020-00176-6
- Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.Mult. Scler. 2016; 22: 830-841https://doi.org/10.1177/1352458515599450
- Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.Mult. Scler. 2016; 22: 659-667https://doi.org/10.1177/1352458515599075
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.Mult. Scler. 2018; 24: 96-120https://doi.org/10.1177/1352458517751049
- Decision-making in multiple sclerosis patients: a systematic review.Mult .Scler. Int. 2018; 20187835952https://doi.org/10.1155/2018/7835952
- Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.Lancet Neurol. 2019; 18: 973-980https://doi.org/10.1016/S1474-4422(19)30151-6
- Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.Ann. Neurol. 2011; 69: 292-302https://doi.org/10.1002/ana.22366
- Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology.Neurology. 2018; 90: 777-788https://doi.org/10.1212/WNL.0000000000005347
- Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.J. Neurol. Neurosurg. Psychiatry. 2002; 73: 701-704https://doi.org/10.1136/jnnp.73.6.701
- Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis.Mult. Scler. Relat. Disord. 2019; 35: 158-163https://doi.org/10.1016/j.msard.2019.07.028
- Measuring productivity loss in early relapsing-remitting multiple sclerosis.Mult. Scler. Relat. Disord. 2022; 58103398https://doi.org/10.1016/j.msard.2021.103398
- The role of prescribing generic (non-proprietary) drugs in the prevalence of therapeutic inertia in multiple sclerosis care.Front. Neurol. 2018; 9: 835https://doi.org/10.3389/fneur.2018.00835
- Overcoming therapeutic inertia in multiple sclerosis care: a pilot randomized trial applying the traffic light system in medical education.Front. Neurol. 2017; 8: 430https://doi.org/10.3389/fneur.2017.00430
- Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS).Front. Neurol. 2017; 8: 65https://doi.org/10.3389/fneur.2017.00065
- Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: a sign of poor self-perception of their clinical status?.Mult. Scler. Relat. Disord. 2020; 45102354https://doi.org/10.1016/j.msard.2020.102354
- Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry.Front. Neurol. 2021; 12693017https://doi.org/10.3389/fneur.2021.693017
- School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis.Mult. Scler. 2015; 21: 945-952https://doi.org/10.1177/1352458514554054
- The hospital anxiety and depression scale.Occup. Med. (Lond). 2014; 64: 393-394https://doi.org/10.1093/occmed/kqu024
- Patient inertia and the status quo bias: when an inferior option is preferred.Psychol. Sci. 2013; 24: 1763-1769https://doi.org/10.1177/0956797613479976
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173https://doi.org/10.1016/S1474-4422(17)30470-2
- Reduced information processing speed as primum movens for cognitive decline in MS.Mult. Scler. 2015; 21: 83-91https://doi.org/10.1177/1352458514537012
- Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review.Mult. Scler. Relat. Disord. 2020; 39101929https://doi.org/10.1016/j.msard.2020.101929
- Patient power revolution in multiple sclerosis: navigating the new frontier.Neurol. Ther. 2018; 7: 179-187https://doi.org/10.1007/s40120-018-0118-8